한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

the sales volume and market share of dr products are in the leading position in the industry, but as the domestic dr market enters the inventory renewal cycle, the sales growth rate has slowed down significantly. wandong medical is facing the end of the "opportunity for high-speed growth" and needs to find a new breakthrough point.

however, weak areas such as ct and mr are the future development direction. wandong medical is trying to find new opportunities in these areas, especially liquid helium-free mr technology, which is widely concerned and expected by the market as a breakthrough technology. however, technological innovation often takes time and investment, and cannot bring huge returns immediately.

overseas markets are also a must for wandong medical. the proportion of international business continues to rise, but the total volume is still very limited. uzbekistan and egypt in central asia have become the target of wandong medical, but whether it can truly achieve localization layout requires further observation.

as the backer behind wandong medical, midea group plays a vital role in future development direction and strategic choices. if wandong medical can prove its value and achieve impressive market results, it will provide important resource support for midea group, and the needs of both parties will be mutually compatible.

however, wandong medical's future is full of challenges. it needs to find new growth points and succeed in overseas markets to get out of trouble and achieve real rapid development.